Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Cambridge, Massachusetts
- Most recent report
- 10-Q, filed Jul 30, 2026
- Incorporated
- Delaware
- Filings on record
- 1,001+ filings
- On EDGAR
- CIK 1439222
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 44
News 8 of 154
- 8-K Quarterly results Jul 30, 2026
- 8-K Leadership change Jun 18, 2026
- 8-K Quarterly results Apr 29, 2026
- 8-K Quarterly results Feb 12, 2026
- 8-K Current report on a material event Jan 12, 2026
- 8-K Quarterly results Oct 30, 2025
- 8-K Current report on a material event Aug 4, 2025
- 8-K Quarterly results Jul 31, 2025
Prospectuses and Registrations 8 of 27
- S-8 Registration statement for an employee plan Jun 18, 2026
- S-3ASR Automatic shelf registration Feb 12, 2026
- S-8 Registration statement for an employee plan Jun 18, 2025
- S-8 Registration statement for an employee plan Mar 5, 2025
- S-8 Registration statement for an employee plan Jun 13, 2023
- S-8 Registration statement for an employee plan Feb 23, 2023
- S-3ASR Automatic shelf registration Feb 23, 2023
- S-8 Registration statement for an employee plan Jan 3, 2023
Proxies 8 of 34
- DEFA14A Extra proxy material Apr 24, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 24, 2026
- DEFA14A Extra proxy material Apr 25, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 25, 2025
- DEFA14A Extra proxy material Apr 26, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 26, 2024
- DEFA14A Extra proxy material Apr 26, 2023
- DEF 14A Proxy statement for a shareholder vote Apr 26, 2023
Ownership 8 of 719
- 4 Insider reported a trade Aug 6, 2026
- 144 Notice of a proposed sale of restricted stock Aug 4, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 3, 2026
- 4 Insider reported a trade Jul 10, 2026
- SCHEDULE 13G Large holder reported a passive stake Jul 2, 2026
- 4 Insider reported a trade Jul 2, 2026
- 144 Notice of a proposed sale of restricted stock Jul 1, 2026
- 4 Insider reported a trade Jun 23, 2026
Other 8 of 23
- ARS Annual report sent to shareholders Apr 24, 2026
- ARS Annual report sent to shareholders Apr 25, 2025
- UPLOAD Comment letter from SEC staff Jun 24, 2024
- CORRESP Reply to SEC staff Jun 11, 2024
- UPLOAD Comment letter from SEC staff May 30, 2024
- ARS Annual report sent to shareholders Apr 26, 2024
- ARS Annual report sent to shareholders Apr 26, 2023
- CT ORDER Sep 10, 2021
Everything here comes from Agios Pharmaceuticals, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.